المؤلفون: Norberto Guelbert, Oscar Mauricio Espitia Segura, Carolina Amoretti, Angélica Arteaga Arteaga, Nora Graciela Atanacio, Sabrina Bazan Natacha, Ellaine Doris Fernandes Carvalho, Maria Denise Fernandes Carvalho de Andrade, Inés María Denzler, Consuelo Durand, Erlane Ribeiro, Juan Carlos Giugni, Gabriel González, Dolores González Moron, Guillermo Guelbert, Zulma Janneth Hernández Rodriguez, Katiane Embiruçu Emilia, Marcelo Andrés Kauffman, Nury Isabel Mancilla, Laureano Marcon, Alessandra Marques Pereira, Carolina Fischinger Moura de Souza, Victor Adrián Muñoz, Ricardo Andrés Naranjo Flórez, André Luiz Pessoa, María Victoria Ruiz, Martha Luz Solano Villareal, Norma Spécola, Lina Marcela Tavera, Javiera Tello, Mónica Troncoso Schifferli, Sonia Ugrina, María Magdalena Vaccarezza, Diane Vergara, María Mercedes Villanueva

المصدر: Molecular Genetics and Metabolism Reports, Vol 38, Iss , Pp 101060- (2024)

مصطلحات موضوعية: Batten disease, Enzyme replacement therapy, Epilepsy, Language delay, Ataxia, Cerliponase alfa, Medicine (General), R5-920, Biology (General), QH301-705.5

الوصف: Introduction: Late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), is a neurodegenerative autosomal recessive disease caused by TPP1 gene variants, with a spectrum of classic and atypical phenotypes. The aim of treatment is to slow functional decline as early as possible in an attempt to improve quality of life and survival. This study describes the clinical characteristics as well as the response to treatment with cerliponase alfa. Materials and methods: A retrospective study was conducted in five Latin-American countries, using clinical records from patients with CLN2. Clinical follow-up and treatment variables are described. A descriptive and bivariate statistical analysis was performed. Results: A total of 36 patients were observed (range of follow-up of 61–110 weeks post-treatment). At presentation, patients with the classic phenotype (n = 16) exhibited regression in language (90%), while seizures were the predominant symptom (87%) in patients with the atypical phenotype (n = 20). Median age of symptom onset and time to first specialized consultation was 3 (classical) and 7 (atypical) years, while the median time interval between onset of symptoms and treatment initiation was 4 years (classical) and 7.5 (atypical). The most frequent variant was c.827 A > T in 17/72 alleles, followed by c.622C > T in 6/72 alleles. All patients were treated with cerliponase alfa, and either remained functionally stable or had a loss of 1 point on the CLN2 scale, or up to 2 points on the Wells Cornel and Hamburg scales, when compared to pretreatment values. Discussion and conclusion: This study reports the largest number of patients with CLN2 currently on treatment with cerliponase alfa in the world. Data show a higher frequency of patients with atypical phenotypes and a high allelic proportion of intron variants in our region. There was evidence of long intervals until first specialized consultation, diagnosis, and enzyme replacement therapy. Follow-up after the initiation of cerliponase alfa showed slower progression or stabilization of the disease, associated with adequate clinical outcomes and stable functional scores. These improvements were consistent in both clinical phenotypes.

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2214426924000132Test; https://doaj.org/toc/2214-4269Test

الوصول الحر: https://doaj.org/article/d1f6513168dd43cd873e78c97646f8bfTest

المؤلفون: Guillermo Guelbert, Ana Clara Venier, Ines Adriana Cismondi, Adriana Becerra, Juan Carlos Vazquez, Elmer Andrés Fernández, Ana Lucía De Paul, Norberto Guelbert, Ines Noher, Favio Pesaola

المصدر: Frontiers in Neurology, Vol 13 (2022)

مصطلحات موضوعية: neuronal ceroid lipofuscinoses (NCL), South America-Caribbean, epidemiology, genotype, phenotype, Neurology. Diseases of the nervous system, RC346-429

الوصف: Neuronal ceroid lipofuscinoses (NCLs) comprise 13 hereditary neurodegenerative pathologies of very low frequency that affect individuals of all ages around the world. All NCLs share a set of symptoms that are similar to other diseases. The exhaustive collection of data from diverse sources (clinical, genetic, neurology, ophthalmology, etc.) would allow being able in the future to define this group with greater precision for a more efficient diagnostic and therapeutic approach. Despite the large amount of information worldwide, a detailed study of the characteristics of the NCLs in South America and the Caribbean region (SA&C) has not yet been done. Here, we aim to present and analyse the multidisciplinary evidence from all the SA&C with qualitative weighting and biostatistical evaluation of the casuistry. Seventy-one publications from seven countries were reviewed, and data from 261 individuals (including 44 individuals from the Cordoba cohort) were collected. Each NCL disease, as well as phenotypical and genetic data were described and discussed in the whole group. The CLN2, CLN6, and CLN3 disorders are the most frequent in the region. Eighty-seven percent of the individuals were 10 years old or less at the onset of symptoms. Seizures were the most common symptom, both at onset (51%) and throughout the disease course, followed by language (16%), motor (15%), and visual impairments (11%). Although symptoms were similar in all NCLs, some chronological differences could be observed. Sixty DNA variants were described, ranging from single nucleotide variants to large chromosomal deletions. The diagnostic odyssey was probably substantially decreased after medical education activities promoted by the pharmaceutical industry and parent organizations in some SA&C countries. There is a statistical deviation in the data probably due to the approval of the enzyme replacement therapy for CLN2 disease, which has led to a greater interest among the medical community for the early description of this pathology. As a general conclusion, it became clear in this work that the combined bibliographical/retrospective evaluation approach allowed a general overview of the multidisciplinary components and the epidemiological tendencies of NCLs in the SA&C region.

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fneur.2022.920421/fullTest; https://doaj.org/toc/1664-2295Test

الوصول الحر: https://doaj.org/article/10be526a07204d988321d4c2cf54b85fTest

المؤلفون: Guillermo Guelbert, Norberto Guelbert

المصدر: Journal of Inborn Errors of Metabolism and Screening, Vol 10 (2022)

مصطلحات موضوعية: Neuronal ceroid lipofuscinosis, CLN, cerliponase alfa, Medicine (General), R5-920

الوصف: Abstract Neuronal ceroid lipofuscinosis type 2 (CLN2) disease is a rare autosomal recessive neurodegenerative disorder caused by mutations in the CLN2/TPP1 gene, leading to a deficiency in tripeptidyl peptidase 1 activity. Enzyme replacement therapy with cerliponase alfa (recombinant human TPP1 [rhTPP1]; Brineura®) was approved in the United States and Europe for the treatment of CLN2 disease in 2017. We retrospectively report a cohort of 19 patients with CLN2 assisted in a specialized center in Argentina, including 8 newly diagnosed cases. Speech disorders and white matter changes/ventricular system enlargement were the most frequent clinical and imaging findings at CLN2 disease onset, respectively. Patients treated with cerliponase alfa presented a stable or improved course of the disease in this Latin American real world setting, as described in clinical trials.

وصف الملف: electronic resource

العلاقة: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2326-45942022000100304&tlng=enTest; https://doaj.org/toc/2326-4594Test

الوصول الحر: https://doaj.org/article/46ef2ff693e44ea6a21f41fb5fe4094dTest

المؤلفون: Favio Pesaola, Guillermo Guelbert, Ana Clara Venier, Inés Adriana Cismondi, Adriana Becerra, Juan Carlos G. Vazquez, Elmer Fernandez, Ana Lucia De Paul, Norberto Guelbert, Inés Noher

المصدر: Journal of Inborn Errors of Metabolism and Screening, Vol 9 (2021)

مصطلحات موضوعية: Neuronal CeroidLipofuscinosis, Genomics, CLN1, CLN2, CLN8, Atypical Phenotypes, Medicine (General), R5-920

الوصف: ABSTRACT Neuronal Ceroid Lipofuscinosis (NCL) refers to a group of inherited lysosomal storage disorders characterized by the intracellular accumulation of ceroid-lipofuscin compounds and neurodegeneration. Fourteen genes are currently recognized with disease-causing DNA variants: PPT1/CLN1, TPP1/CLN2, CLN3, DNAJC5/CLN4, CLN5, CLN6, MFSD8/CLN7, CLN8, CTSD/CN10, GRN/CLN11, ATP13A2/CLN12, CTSF/CLN13, KCTD7/CLN14, TBCK/CLN15. In the frame of the Cordoba cohort, we studied N=51 cases. The aim of this paper is the observational and retrospective analysis of the “atypical” phenotypes. PCR-Sanger sequencing and/or massive exome sequencing were used as a screening methodology. One CLN1 subject showed an atypical prolonged (P) phenotype with null PPT1 activity and a heterozygous compound genotype: E5 c.451C>T, p.Arg151*/g.6302T>G (I3 c.363-3T>G). Other 11 CLN2 individuals (except one girl) showed TPP1 activity decreased to around 10% of the minimum value of the reference interval in leukocytes and saliva. The DNA variants E7 c.827A>T, p.Asp276Val and I7 c.887-10A>G were the most prevalent. One CLN8 individual showed an atypical congenital phenotype with a heterozygous combination of DNA variants: E2 c.1A>G, p.?/E3 c.792C>G, p.Asn264Lys. Massive sequencing was installed as a screening methodology for the precision diagnosis of atypical CLN1, CLN2, and CLN8 phenotypes. A genetic/phenotypic local registry is under construction.

وصف الملف: electronic resource

العلاقة: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2326-45942021000100308&tlng=enTest; https://doaj.org/toc/2326-4594Test

الوصول الحر: https://doaj.org/article/98139ce7c9a94aa784ae9d56f4a1dc8cTest

المؤلفون: Norberto Guelbert, Oscar M Espitia Segura, Carolina Amoretti, Angélica Arteaga Arteaga, Nora G Atanacio, Natacha S Bazan, Ellaine D.F Carvalho, María D. F Carvalho de Andrade, Inés M Denzler, Consuelo Durand, Erlane M Ribeiro, Juan C Giugni, Gabriel González, Dolores González Moron, Guillermo Guelbert, Zulma J Hernández Rodriguez, Emilia K Embiruçu, Marcelo A Kauffman, Nury I Mancilla, Laureano Marcon, Alessandra Marques Pereira, Carolina F Fischinger Moura de Souza, Victor A Muñoz, Ricardo A Naranjo Florez, André L Pessoa, Maria V Ruiz, Martha M Solano Villareal, Norma Spécola, Lina M Tavera, Javiera Tello, Mónica Troncoso Schifferli, Sonia Urgrina, María M Vaccarezza, Diane Vergara, María M Villanueva

الوصف: Introduction: Late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), is a neurodegenerative autosomal recessive disease caused by TPP1 gene variants, with a spectrum of classic and atypical phenotypes. The aim of treatment is to slow functional decline as early as possible, improving quality of life and survival. This study describes the clinical characteristics as well as response to treatment with cerliponase alfa. Materials and Methods: A retrospective study was conducted in five Latin-American countries, based on clinical records from patients with CLN2. Clinical follow-up and treatment variables are described. A descriptive and bivariate statistical analysis was performed. Results: A total of 36 patients are reported with a mean age of symptom onset and time to first specialized consultation of 4.7±2.3 and 6±3.1 years, respectively. Seizures were the predominant symptom (80.6%). In a subgroup analysis, most patients with the classic phenotype exhibited regression in language (90%), while the patients with the atypical phenotype had seizures as the predominant symptom (87%). The mean age of symptom onset and time to first specialized consultation was 3.5±2.0 and 4.9±3.2 years, respectively, in patients with the classic phenotype and 6.2±1.8 and 7.5±2.4 in patients with the atypical phenotype. The mean time interval between onset of symptoms and treatment initiation was 3.8 years in patients with classic phenotype and 7.4 in patients with atypical phenotype. All patients were treated with cerliponase alfa, maintaining overall functional stability as compared to pretreatment values. Discussion and conclusion: This study reports at this time the largest number of patients with CLN2 in treatment with cerliponase alfa in the world. Data show a higher frequency of patients with atypical phenotype and a high allelic proportion of intron variants in our region. There was evidence of long intervals until first specialized consultation, diagnosis, and enzyme replacement therapy. Follow-up after the initiation of cerliponase alfa showed slower-to-no-progression of the disease, associated with adequate clinical outcomes and stable functional scores. These improvements were consistent in both clinical phenotypes.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::51af08e74ac01947826084e752e49bf4Test
https://doi.org/10.21203/rs.3.rs-2159184/v1Test

المؤلفون: Guillermo Guelbert, Ana Clara Venier, Ines Adriana Cismondi, Adriana Becerra, Juan Carlos Vazquez, Elmer Andrés Fernández, Ana Lucía De Paul, Norberto Guelbert, Ines Noher, Favio Pesaola

مصطلحات موضوعية: Neurology and Neuromuscular Diseases, Neurogenetics, neuronal ceroid lipofuscinoses (NCL), South America-Caribbean, epidemiology, genotype, phenotype

الوصف: Neuronal ceroid lipofuscinoses (NCLs) comprise 13 hereditary neurodegenerative pathologies of very low frequency that affect individuals of all ages around the world. All NCLs share a set of symptoms that are similar to other diseases. The exhaustive collection of data from diverse sources (clinical, genetic, neurology, ophthalmology, etc.) would allow being able in the future to define this group with greater precision for a more efficient diagnostic and therapeutic approach. Despite the large amount of information worldwide, a detailed study of the characteristics of the NCLs in South America and the Caribbean region (SA&C) has not yet been done. Here, we aim to present and analyse the multidisciplinary evidence from all the SA&C with qualitative weighting and biostatistical evaluation of the casuistry. Seventy-one publications from seven countries were reviewed, and data from 261 individuals (including 44 individuals from the Cordoba cohort) were collected. Each NCL disease, as well as phenotypical and genetic data were described and discussed in the whole group. The CLN2, CLN6, and CLN3 disorders are the most frequent in the region. Eighty-seven percent of the individuals were 10 years old or less at the onset of symptoms. Seizures were the most common symptom, both at onset (51%) and throughout the disease course, followed by language (16%), motor (15%), and visual impairments (11%). Although symptoms were similar in all NCLs, some chronological differences could be observed. Sixty DNA variants were described, ranging from single nucleotide variants to large chromosomal deletions. The diagnostic odyssey was probably substantially decreased after medical education activities promoted by the pharmaceutical industry and parent organizations in some SA&C countries. There is a statistical deviation in the data probably due to the approval of the enzyme replacement therapy for CLN2 disease, which has led to a greater interest among the medical community for the early description of this pathology. As ...

العلاقة: https://figshare.com/articles/figure/Image_1_Neuronal_ceroid_lipofuscinosis_in_the_South_American-Caribbean_region_An_epidemiological_overview_TIF/20478969Test

الإتاحة: https://doi.org/10.3389/fneur.2022.920421.s002Test
https://figshare.com/articles/figure/Image_1_Neuronal_ceroid_lipofuscinosis_in_the_South_American-Caribbean_region_An_epidemiological_overview_TIF/20478969Test

المؤلفون: Guillermo Guelbert, Ana Clara Venier, Ines Adriana Cismondi, Adriana Becerra, Juan Carlos Vazquez, Elmer Andrés Fernández, Ana Lucía De Paul, Norberto Guelbert, Ines Noher, Favio Pesaola

مصطلحات موضوعية: Neurology and Neuromuscular Diseases, Neurogenetics, neuronal ceroid lipofuscinoses (NCL), South America-Caribbean, epidemiology, genotype, phenotype

الوصف: Neuronal ceroid lipofuscinoses (NCLs) comprise 13 hereditary neurodegenerative pathologies of very low frequency that affect individuals of all ages around the world. All NCLs share a set of symptoms that are similar to other diseases. The exhaustive collection of data from diverse sources (clinical, genetic, neurology, ophthalmology, etc.) would allow being able in the future to define this group with greater precision for a more efficient diagnostic and therapeutic approach. Despite the large amount of information worldwide, a detailed study of the characteristics of the NCLs in South America and the Caribbean region (SA&C) has not yet been done. Here, we aim to present and analyse the multidisciplinary evidence from all the SA&C with qualitative weighting and biostatistical evaluation of the casuistry. Seventy-one publications from seven countries were reviewed, and data from 261 individuals (including 44 individuals from the Cordoba cohort) were collected. Each NCL disease, as well as phenotypical and genetic data were described and discussed in the whole group. The CLN2, CLN6, and CLN3 disorders are the most frequent in the region. Eighty-seven percent of the individuals were 10 years old or less at the onset of symptoms. Seizures were the most common symptom, both at onset (51%) and throughout the disease course, followed by language (16%), motor (15%), and visual impairments (11%). Although symptoms were similar in all NCLs, some chronological differences could be observed. Sixty DNA variants were described, ranging from single nucleotide variants to large chromosomal deletions. The diagnostic odyssey was probably substantially decreased after medical education activities promoted by the pharmaceutical industry and parent organizations in some SA&C countries. There is a statistical deviation in the data probably due to the approval of the enzyme replacement therapy for CLN2 disease, which has led to a greater interest among the medical community for the early description of this pathology. As ...

العلاقة: https://figshare.com/articles/dataset/Table_1_Neuronal_ceroid_lipofuscinosis_in_the_South_American-Caribbean_region_An_epidemiological_overview_XLSX/20478990Test

الإتاحة: https://doi.org/10.3389/fneur.2022.920421.s006Test
https://figshare.com/articles/dataset/Table_1_Neuronal_ceroid_lipofuscinosis_in_the_South_American-Caribbean_region_An_epidemiological_overview_XLSX/20478990Test

المؤلفون: Guillermo Guelbert, Ana Clara Venier, Ines Adriana Cismondi, Adriana Becerra, Juan Carlos Vazquez, Elmer Andrés Fernández, Ana Lucía De Paul, Norberto Guelbert, Ines Noher, Favio Pesaola

مصطلحات موضوعية: Neurology and Neuromuscular Diseases, Neurogenetics, neuronal ceroid lipofuscinoses (NCL), South America-Caribbean, epidemiology, genotype, phenotype

الوصف: Neuronal ceroid lipofuscinoses (NCLs) comprise 13 hereditary neurodegenerative pathologies of very low frequency that affect individuals of all ages around the world. All NCLs share a set of symptoms that are similar to other diseases. The exhaustive collection of data from diverse sources (clinical, genetic, neurology, ophthalmology, etc.) would allow being able in the future to define this group with greater precision for a more efficient diagnostic and therapeutic approach. Despite the large amount of information worldwide, a detailed study of the characteristics of the NCLs in South America and the Caribbean region (SA&C) has not yet been done. Here, we aim to present and analyse the multidisciplinary evidence from all the SA&C with qualitative weighting and biostatistical evaluation of the casuistry. Seventy-one publications from seven countries were reviewed, and data from 261 individuals (including 44 individuals from the Cordoba cohort) were collected. Each NCL disease, as well as phenotypical and genetic data were described and discussed in the whole group. The CLN2, CLN6, and CLN3 disorders are the most frequent in the region. Eighty-seven percent of the individuals were 10 years old or less at the onset of symptoms. Seizures were the most common symptom, both at onset (51%) and throughout the disease course, followed by language (16%), motor (15%), and visual impairments (11%). Although symptoms were similar in all NCLs, some chronological differences could be observed. Sixty DNA variants were described, ranging from single nucleotide variants to large chromosomal deletions. The diagnostic odyssey was probably substantially decreased after medical education activities promoted by the pharmaceutical industry and parent organizations in some SA&C countries. There is a statistical deviation in the data probably due to the approval of the enzyme replacement therapy for CLN2 disease, which has led to a greater interest among the medical community for the early description of this pathology. As ...

العلاقة: https://figshare.com/articles/dataset/Data_Sheet_1_Neuronal_ceroid_lipofuscinosis_in_the_South_American-Caribbean_region_An_epidemiological_overview_PDF/20478966Test

الإتاحة: https://doi.org/10.3389/fneur.2022.920421.s001Test
https://figshare.com/articles/dataset/Data_Sheet_1_Neuronal_ceroid_lipofuscinosis_in_the_South_American-Caribbean_region_An_epidemiological_overview_PDF/20478966Test

المؤلفون: Guillermo Guelbert, Adriana Becerra, Favio Pesaola, Ana Clara Venier, Ana Lucía De Paul, Inés Adriana Cismondi, Ines Noher, Juan Carlos G. Vazquez, Norberto Guelbert, Elmer Andrés Fernández

المصدر: Journal of Inborn Errors of Metabolism and Screening v.9 2021
Journal of Inborn Errors of Metabolism and Screening
Instituto Genética para Todos (IGPT)
instacron:IGPT
Repositorio Digital Universitario (UNC)
Universidad Nacional de Córdoba
instacron:UNC
Journal of Inborn Errors of Metabolism and Screening, Volume: 9, Article number: e20210009, Published: 05 MAY 2021
Journal of Inborn Errors of Metabolism and Screening, Vol 9 (2021)

مصطلحات موضوعية: Genetics, Atypical Phenotypes, Medicine (General), KCTD7, CLN1, Endocrinology, Diabetes and Metabolism, CLN2, PPT1, Neuronal Ceroid Lipofuscinosis, Genomics, Biology, medicine.disease, Phenotype, CLN8, R5-920, Neuronal CeroidLipofuscinosis, Pediatrics, Perinatology and Child Health, Genotype, medicine, Neuronal ceroid lipofuscinosis, Gene, Genetics (clinical), Exome sequencing

الوصف: Neuronal Ceroid Lipofuscinosis (NCL) refers to a group of inherited lysosomal storage disorders characterized by the intracellular accumulation of ceroid-lipofuscin compounds and neurodegeneration. Fourteen genes are currently recognized with disease-causing DNA variants: PPT1/CLN1, TPP1/CLN2, CLN3, DNAJC5/CLN4, CLN5, CLN6, MFSD8/CLN7, CLN8, CTSD/CN10, GRN/CLN11, ATP13A2/CLN12, CTSF/CLN13, KCTD7/CLN14, TBCK/CLN15. In the frame of the Cordoba cohort, we studied N=51 cases. The aim of this paper is the observational and retrospective analysis of the “atypical” phenotypes. PCR-Sanger sequencing and/or massive exome sequencing were used as a screening methodology. One CLN1 subject showed an atypical prolonged (P) phenotype with null PPT1 activity and a heterozygous compound genotype: E5 c.451C>T, p.Arg151*/g.6302T>G (I3 c.363-3T>G). Other 11 CLN2 individuals (except one girl) showed TPP1 activity decreased to around 10% of the minimum value of the reference interval in leukocytes and saliva. The DNA variants E7 c.827A>T, p.Asp276Val and I7 c.887-10A>G were the most prevalent. One CLN8 individual showed an atypical congenital phenotype with a heterozygous combination of DNA variants: E2 c.1A>G, p.?/E3 c.792C>G, p.Asn264Lys. Massive sequencing was installed as a screening methodology for the precision diagnosis of atypical CLN1, CLN2, and CLN8 phenotypes. A genetic/phenotypic local registry is under construction. publishedVersion Fil: Pesaola, Favio. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigación en Ciencias de la Salud; Argentina. Fil: Pesaola, Favio. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas; Argentina. Fil: Pesaola, Favio. Hospital de Niños de la Provincia de Córdoba. Programa de Investigación Traslacional de Lipofuscinosis Ceroideas Neuronales; Argentina. Fil: Guelbert, Guillermo. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas; Argentina. Fil: Guelbert, Guillermo. Hospital de Niños de la Provincia de Córdoba. Programa de Investigación Traslacional de Lipofuscinosis Ceroideas Neuronales; Argentina. Fil: Guelbert, Guillermo. Hospital de Niños de la Provincia de Córdoba. Sección de Enfermedades Metabólicas Hereditarias; Argentina. Fil: Venier, Ana Clara. Universidad Nacional de Córdoba. Facultad de Ciencias Exactas, Físicas y Naturales; Argentina. Fil: Venier, Ana Clara. Hospital de Niños de la Provincia de Córdoba. Programa de Investigación Traslacional de Lipofuscinosis Ceroideas Neuronales; Argentina. Fil: Venier, Ana Clara. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigación en Ciencias de la Salud; Argentina. Fil: Cismondi, Inés Adriana. Universidad Nacional de Córdoba. Facultad de Odontología; Argentina. Fil: Cismondi, Inés Adriana. Hospital de Niños de la Provincia de Córdoba. Programa de Investigación Traslacional de Lipofuscinosis Ceroideas Neuronales; Argentina. Fil: Becerra, Adriana. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas; Argentina. Fil: Beccera, Adriana. Hospital de Niños de la Provincia de Córdoba. Programa de Investigación Traslacional de Lipofuscinosis Ceroideas Neuronales; Argentina. Fil: Becerra, Adriana. Hospital de Niños de la Provincia de Córdoba. Sección de Enfermedades Metabólicas Hereditarias; Argentina. Fil: Vazquez, Juan Carlos G. Universidad Católica de Córdoba; Argentina. Fil: Vazquez, Juan Carlos G. Consejo Nacional de Investigaciones Científicas y Técnicas, Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas; Argentina. Fil: Fernández, Elmer. Universidad Católica de Córdoba; Argentina. Fil: Fernández, Elmer. Consejo Nacional de Investigaciones Científicas y Técnicas, Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas; Argentina. Fil: De Paul, Ana Lucia. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Centro de Microscopía Electrónica; Argentina. Fil: De Paul, Ana Lucia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigación en Ciencias de la Salud; Argentina. Fil: Guelbert, Norberto. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas; Argentina. Fil: Guelbert, Norberto. Hospital de Niños de la Provincia de Córdoba. Programa de Investigación Traslacional de Lipofuscinosis Ceroideas Neuronales; Argentina. Fil: Guelbert, Norberto. Clínica Universitaria Reina Fabiola; Argentina. Fil: Noher, Inés. Fil: Venier, Universidad Nacional de Córdoba. Facultad de Ciencias Exactas, Físicas y Naturales; Argentina. Fil: Noher, Inés. Hospital de Niños de la Provincia de Córdoba. Programa de Investigación Traslacional de Lipofuscinosis Ceroideas Neuronales; Argentina.

وصف الملف: text/html; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b45888f3d773e07c06b990cb4c0df23aTest
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2326-45942021000100308Test

المؤلفون: Victor Munoz, Guillermo Guelbert, Francisco Pueyrredon, Guillermo Seratti, Roberto Caraballo, Norberto Guelbert, Raul Jalil, Tatiana Rodrigo, Daniel Velazquez

المصدر: Molecular Genetics and Metabolism. 123:S128

مصطلحات موضوعية: Pediatrics, medicine.medical_specialty, business.industry, Endocrinology, Diabetes and Metabolism, Disease, Enzyme replacement therapy, Cerliponase alfa, Biochemistry, Neuronal Ceroid Lipofuscinosis Type 2, Endocrinology, Public hospital, Genetics, Medicine, business, Molecular Biology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::1efc7cefb0cb611f6174c8bfcdd184beTest
https://doi.org/10.1016/j.ymgme.2017.12.349Test